Effects of Neoadjuvant Chemotherapy on Hepatoblastoma: A Morphologic and Immunohistochemical Study

Neoadjuvant chemotherapy followed by resection has become the mainstay in the treatment of hepatoblastoma (HB). The changes after chemotherapy typically result in tumor necrosis and a fibrohistiocytic response. We have observed that treated HBs undergo additional morphologic changes that have not been described. Herein, we report a 15-year retrospective study of HBs in 22 children who received neoadjuvant chemotherapy according to the Children's Oncology Group protocols. The medical records, diagnostic imaging, and histopathology were reviewed. Besides treated HBs having characteristic necrosis and fibrohistiocytic response, two-thirds had areas of cytoarchitectural differentiation (“maturation”) mimicking non-neoplastic liver, and a quarter had alterations mimicking hepatocellular carcinoma. Nuclear expression of β-catenin and keratin profiles were useful in distinguishing residual tumor with “maturation” from non-neoplastic liver and therefore in the assessment of surgical margins. Statistical analysis revealed that larger pretreatment and posttreatment imaged tumor size, larger tumor size at pathologic examination, and vascular invasion were significant univariate predictors of metastatic disease, whereas pretreatment imaged tumor size and vascular invasion were also significant independent predictors (multivariate logistic regression analysis). Multifocality, greater posttreatment necrosis and hepatocellular carcinoma-like morphology were more often associated with metastatic disease, but did not reach statistical significance.

[1]  S. Sredni,et al.  Hepatoblastomas and Liver Development: A Study of Cytokeratin Immunoexpression in Twenty-Nine Hepatoblastomas , 2006, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[2]  G. Perilongo,et al.  Hepatoblastoma: an oncological review , 2006, Pediatric Radiology.

[3]  E. Montgomery,et al.  The Diagnostic Value of β-Catenin Immunohistochemistry , 2005, Advances in anatomic pathology.

[4]  S. Ranganathan,et al.  β-Catenin and Met Deregulation in Childhood Hepatoblastomas , 2005 .

[5]  S. Ranganathan,et al.  beta-Catenin and met deregulation in childhood Hepatoblastomas. , 2005, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[6]  D. V. von Schweinitz,et al.  Stem-like Cells in Human Hepatoblastoma , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[7]  K. Furuuchi,et al.  Nuclear accumulation of beta-catenin without an additional somatic mutation in coding region of the APC gene in hepatoblastoma from a familial adenomatous polyposis patient. , 2004, Oncology reports.

[8]  D. V. von Schweinitz,et al.  Where do we stand with hepatoblastoma? , 2003, Cancer.

[9]  T G Clark,et al.  Survival Analysis Part I: Basic concepts and first analyses , 2003, British Journal of Cancer.

[10]  James R. Anderson,et al.  Cytodifferentiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS). , 2002, Medical and pediatric oncology.

[11]  H. S. Kim,et al.  Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma. , 2001, The Journal of pathology.

[12]  A. Nakagawara,et al.  Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  T. Pysher,et al.  Therapy Associated Changes in Childhood Tumors , 2000, Advances in anatomic pathology.

[14]  T. Triche,et al.  Presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma: implications for the outcome. , 2000, Journal of pediatric hematology/oncology.

[15]  J. Rulon,et al.  Pathologic features of rhabdomyosarcoma before and after treatment: a clinicopathologic and immunohistochemical analysis. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[16]  J. Grosfeld,et al.  Hepatoblastoma: the Indiana experience with preoperative chemotherapy for inoperable tumors; clinicopathological considerations. , 1997, Pediatric pathology & laboratory medicine : journal of the Society for Pediatric Pathology, affiliated with the International Paediatric Pathology Association.

[17]  P. Ruck,et al.  Small epithelial cells and the histogenesis of hepatoblastoma. Electron microscopic, immunoelectron microscopic, and immunohistochemical findings. , 1996, The American journal of pathology.

[18]  M. Davenport,et al.  Chemotherapy Effects on Hepatoblastoma: A Histological Study , 1993, The American journal of surgical pathology.

[19]  A. Alberti,et al.  Cytokeratins patterns in childhood primary liver tumors , 1993, International journal of clinical & laboratory research.

[20]  D. Luckey,et al.  The effect of preoperative therapy on the histologic features of wilms' tumor. An analysis of cases from the third national Wilms' tumor study , 1991, Cancer.

[21]  C. Fisher,et al.  Retroconversion of immature teratoma of the ovary: CT appearances. , 1991, Clinical radiology.

[22]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[23]  K. Muczynski,et al.  Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma , 1989, Cancer.

[24]  J. Chantelard,et al.  [Maturation of immature teratomas of the ovary. Apropos of a case and review of the literature]. , 1987, Journal de gynecologie, obstetrique et biologie de la reproduction.

[25]  M. Upton,et al.  Hepatoblastoma: Attempt at characterization of histologic subtypes , 1982, The American journal of surgical pathology.

[26]  J. Diagnostic Immunohistochemistry , 2022 .